Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)
Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@novonordisk.com(+1) 866-867-7178
Ciudad Autonoma de Buenos Aires, Buenos Aires C1018ADE, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C1424CIQ, Argentina
Mar del Plata, Buenos Aires B7600FZN, Argentina
Sofia, 1431, Bulgaria
Køge, Region Sjælland 4600, Denmark
Esbjerg, Region Syddanmark 6700, Denmark
Clermont-Ferrand, 63000, France
La Tronche, 38700, France
Le Creusot, 71200, France
Lille, 59000, France
Speyer, LÄK Rheinland-Pfalz 67346, Germany
Lingen, 49808, Germany
Oldenburg in Holstein, 23758, Germany
Saint Ingbert-Oberwürzbach, 66386, Germany
Ferrara, Emilia-Romagna 44124, Italy
Genoa, Liguria 16132, Italy
Pavia, Lombardy 27100, Italy
Palermo, Sicily 90127, Italy
Padova, Veneto 35128, Italy
Verona, Veneto 37126, Italy
Cheshire, CH65 4LE, United Kingdom